ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.522,42
-0,42%
S&P 500
5.631,22
0,28%
Dow Jones
40.211,72
0,53%
Euro vs US Dollar
1,09005
0,01%
Bitcoin
63.571,10
-1,97%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Sana Biotechnology Inc (SANA)

  7. Sana Biotechnology Inc (SANA) News

SANA

Sana Biotechnology (SANA)

Sana Biotechnology Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SANA
DatumZeitQuelleÜberschriftSymbolFirma
14/03/202321h53GlobeNewswire Inc.Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual MeetingNASDAQ:SANASana Biotechnology Inc
03/03/202322h40Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SANASana Biotechnology Inc
03/03/202322h39Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SANASana Biotechnology Inc
03/03/202322h39Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SANASana Biotechnology Inc
03/03/202322h38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SANASana Biotechnology Inc
01/03/202322h05GlobeNewswire Inc.Sana Biotechnology to Present at the Cowen 43rd Annual Health Care ConferenceNASDAQ:SANASana Biotechnology Inc
09/02/202314h16Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SANASana Biotechnology Inc
02/02/202322h05GlobeNewswire Inc.Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology ConferenceNASDAQ:SANASana Biotechnology Inc
26/01/202322h17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SANASana Biotechnology Inc
26/01/202322h17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SANASana Biotechnology Inc
26/01/202322h05GlobeNewswire Inc.Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell MalignanciesNASDAQ:SANASana Biotechnology Inc
20/01/202313h42Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SANASana Biotechnology Inc
03/01/202322h05GlobeNewswire Inc.Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:SANASana Biotechnology Inc
11/12/202223h30GlobeNewswire Inc.Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual MeetingNASDAQ:SANASana Biotechnology Inc
29/11/202222h05GlobeNewswire Inc.Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio PrioritizationNASDAQ:SANASana Biotechnology Inc
14/11/202222h05GlobeNewswire Inc.Sana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer CategoryNASDAQ:SANASana Biotechnology Inc
03/11/202214h07GlobeNewswire Inc.Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual MeetingNASDAQ:SANASana Biotechnology Inc
02/11/202221h20Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SANASana Biotechnology Inc
02/11/202221h12Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SANASana Biotechnology Inc
02/11/202221h05GlobeNewswire Inc.Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business UpdatesNASDAQ:SANASana Biotechnology Inc
01/11/202221h07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SANASana Biotechnology Inc
06/10/202222h07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SANASana Biotechnology Inc
17/09/202200h53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SANASana Biotechnology Inc
17/09/202200h52Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SANASana Biotechnology Inc
09/09/202222h05GlobeNewswire Inc.Sana Biotechnology to Present at September 2022 Investor ConferencesNASDAQ:SANASana Biotechnology Inc
04/08/202223h28Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:SANASana Biotechnology Inc
04/08/202222h43Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SANASana Biotechnology Inc
04/08/202222h05GlobeNewswire Inc.Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business UpdatesNASDAQ:SANASana Biotechnology Inc
07/07/202222h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SANASana Biotechnology Inc
17/06/202215h00GlobeNewswire Inc.Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human PrimatesNASDAQ:SANASana Biotechnology Inc
 Showing the most relevant articles for your search:NASDAQ:SANA

Kürzlich von Ihnen besucht

COIN
SOLUSD
Solana
TG
DTE
Deutsche Telekom
AMEX
XLV
Health Care Select Sector
NYSE
JPM
JP Morgan Chase
DBI
TDXP
Tec DAX
TG
DBK
Deutsche Bank
TG
CBK
Commerzbank
NYSE
DIS
Walt Disney
NASDAQ
MSFT
Microsoft
CCOM
US100
US Tech 100
TG
LHA
Deutsche Lufthansa
USOTC
RHHBY
Roche (QX)
NASDAQ
AMZN
Amazon.com
USOTC
DTEGY
Deutsche Telekom (QX)
AMEX
XLE
Energy Select Sector SPDR
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten